{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:35:39Z","timestamp":1776512139233,"version":"3.51.2"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.clinthera.2013.06.017","type":"journal-article","created":{"date-parts":[[2013,8,2]],"date-time":"2013-08-02T04:16:55Z","timestamp":1375417015000},"page":"1211-1222.e2","source":"Crossref","is-referenced-by-count":38,"title":["Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects"],"prefix":"10.1016","volume":"35","author":[{"given":"Li","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh","family":"Bui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sreeneeranj","family":"Kasichayanula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C.","family":"Griffen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank P.","family":"LaCreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Boulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.06.017_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2013.06.017_bib2","first-page":"678","article-title":"A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China","volume":"11","year":"1981","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.clinthera.2013.06.017_bib3","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362","author":"Yang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.06.017_bib4","unstructured":"International Diabetes Federation. IDF Diabetes Atlas: Fifth Edition. 2011. http:\/\/www.idf.org\/atlasmap\/atlasmap. Accessed September 11, 2012."},{"key":"10.1016\/j.clinthera.2013.06.017_bib5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.06.017_bib6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.06.017_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2013.06.017_bib8","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/ndt\/gfh426","article-title":"A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria","volume":"19","author":"Francis","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2013.06.017_bib9","first-page":"156","article-title":"Complete absence of tubular glucose reabsorption: a new type of renal glucosuria (type 0)","volume":"27","author":"Oemar","year":"1987","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clinthera.2013.06.017_bib10","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1093\/ndt\/gfh366","article-title":"Long-term outcome of renal glucosuria type 0: the original patient and his natural history","volume":"19","author":"Scholl-Burgi","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.06.017_bib11","first-page":"A286","article-title":"Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, Has a Low Propensity To Cause Hypoglycemia in Patients with Type 2 Diabetes","volume":"60","author":"Rohwedder","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2013.06.017_bib12","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.06.017_bib13","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2013.06.017_bib14","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2013.06.017_bib15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2013.06.017_bib16","article-title":"Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes","volume":"60","author":"Rosenstock","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2013.06.017_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2013.06.017_bib18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2013.06.017_bib19","doi-asserted-by":"crossref","first-page":"A9520","DOI":"10.1161\/circ.124.suppl_21.A9520","article-title":"Dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus","volume":"124","author":"Woo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2013.06.017_bib20","unstructured":"Bristol-Myers Squibb. Forxiga (dapagliflozin) [product information]. http:\/\/www.forxiga.eu\/Forxiga%20Summary%20of%20Product%20Characteristics_SmPC_.pdf. Accessed March 8, 2013."},{"key":"10.1016\/j.clinthera.2013.06.017_bib21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1463-1326.2011.01397.x","article-title":"Effect of a high-fat meal on the pharmacokinetics of dapagliflozin, a selective SGLT2 inhibitor, in healthy subjects","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2013.06.017_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/dmd.109.029165","article-title":"In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans","volume":"38","author":"Obermeier","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2013.06.017_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2013.06.017_bib24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","article-title":"A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment","volume":"32","author":"Wilding","year":"2009","journal-title":"Diabetes Care"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813003457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T22:37:09Z","timestamp":1715812629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813003457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0149291813003457"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.06.017","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}